Hypoxia derived HIF-1α is an important factor not only in the fibrotic microenvironment but also in the tumor microenvironment that causes cancer or metastasis, and in clinically lung cancer often occurs as lung fibrosis progresses. In fact it has been extremely difficult to even treat effectively with few treatment options, and the development of a treatment for these complications is urgent. ACH253 is a new chemical entity designed and synthesized by researchers at Achembio to this end. The efficacy, safety, and mechanism of action of ACH253 are currently being evaluated and will be updated as soon as related data are released.